Post-mastectomy radiotherapy

Clinical Advances in Hematology and Oncology

Volumn 7, Issue 8, 2009, Pages 533-543

  Zellars, Richard ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Breast cancer; Post mastectomy; Radiation; Toxicity

Indexed keywords

ANTHRACYCLINE DERIVATIVE; CORTICOSTEROID DERIVATIVE; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; HYALURONIC ACID; METHOTREXATE; PACLITAXEL; PLACEBO; SULFADIAZINE SILVER; TAMOXIFEN; TRASTUZUMAB; TRIETHANOLAMINE SALICYLATE;

BREAST CANCER; BREAST FIBROSIS; BRONCHIOLITIS OBLITERANS ORGANIZING PNEUMONIA; CANADA; CANCER MORTALITY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL EFFECTIVENESS; CLINICAL STUDY; CLINICAL TRIAL; COMPRESSION THERAPY; FOLLOW UP; HUMAN; LYMPH NODE IRRADIATION; LYMPHEDEMA; OVERALL SURVIVAL; POST MASTECTOMY RADIOTHERAPY; RADIATION DERMATITIS; RADIATION PNEUMONIA; REVIEW; RIB FRACTURE; SENTINEL LYMPH NODE BIOPSY; SKIN TOXICITY;

BREAST NEOPLASMS; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; FEMALE; HUMANS; MASTECTOMY; RADIOTHERAPY, ADJUVANT;

EID: 70349680615     PISSN: 15430790     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (99)

1. Fisher B, Slack NH, Cavanaugh PJ, et al. Postoperative radiotherapy in the treatment of breast cancer: Results of the NSABP clinical trial. Ann Surg. 1970;172:711-732.
2. Cuzick J, Stewart H, Peto R, et al. Overview of randomized trials comparing radical mastectomy without radiotherapy against simple mastectomy with radiotherapy in breast cancer. Cancer Treat Rep. 1987;71:7-14.
3. Cuzick J, Stewart H, Rutqvist L, et al. Cause-specific mortality in long-term survivors of breast cancer who participated in trials of radiotherapy. J Clin Oncol. 1994;12:447-453.
4. Haagensen CD, Bodian C. A personal experience with halsted's radical mastectomy. Ann Surg. 1984;199:143-150.
5. Overgaard M, Hansen PS, Overgaard J, et al. Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. dDanish breast cancer cooperative group 82b trial. N Engl J Med. 1997;337:949-955.
6. Overgaard M. Overview of randomized trials in high risk breast cancer patients treated with adjuvant systemic therapy with or without postmastectomy irradiation. Semin Radiat Oncol. 1999;9:292-299.
7. Ragaz J, Olivotto IA, Spinelli JJ, et al. Locoregional radiation therapy in patients with high-risk breast cancer receiving adjuvant chemotherapy: 20-year results of the british columbia randomized trial. J Natl Cancer Inst. 2005;97:116-126.
8. Taghian A, Jeong JH, Mamounas E, et al. Patterns of locoregional failure in patients with operable breast cancer treated by mastectomy and adjuvant chemotherapy with or without tamoxifen and without radiotherapy: Results from five national surgical adjuvant breast and bowel project randomized clinical trials. J Clin Oncol. 2004;22:4247-4254.
9. Recht A, Gray R, Davidson NE, et al. Locoregional failure 10 years after mastectomy and adjuvant chemotherapy with or without tamoxifen without irradiation: Experience of the eastern cooperative oncology group. J Clin Oncol. 1999;17:1689-1700.
10. Ceilley E, Jagsi R, Goldberg S, et al. Radiotherapy for invasive breast cancer in north america and europe: Results of a survey. Int J Radiat Oncol Biol Phys. 2005;61:365-373.
11. Kunkler IH, Canney P, van Tienhoven G, et al. Elucidating the role of chest wall irradiation in 'intermediate-risk' breast cancer: The MRC/ EORTC SUPREMO trial. Clin Oncol (R Coll Radiol). 2008;20:31-34.
12. Chung CS, Harris JR. Post-mastectomy radiation therapy: Translating local benefits into improved survival. Breast. 2007;16 Suppl 2:S78-83.
13. Overgaard M, Nielsen HM, Overgaard J. Is the benefit of postmastectomy irradiation limited to patients with four or more positive nodes, as recommended in international consensus reports? A subgroup analysis of the DBCG 82 b&c randomized trials. Radiother Oncol. 2007;82:247-253.
14. McGale P. The 2006 worldwide overview of the effects of local treatments for early breast cancer on long-term outcome- "meta-analysis of the randomized trials of radiotherapy after mastectomy with axillary clearance". Annual Meetings of the American Society for Therapeutic Radiology and Oncology. November 6, 2006.
15. Buchholtz TA, Woodward WA, Duan Z, et al. Radiation use and long-term survival in breast cancer patients with T1, T2 primary tumors and 1-3 positive axillary lymph nodes. Int J Radiat Oncol Biol Phys. 2006;66:S5.
16. Marks LB, Zeng J, Prosnitz LR. One to three versus four or more positive nodes and postmastectomy radiotherapy: Time to end the debate. J Clin Oncol. 2008;26:2075-2077.
17. Woodward WA, Vinh-Hung V, Ueno NT, et al. Prognostic value of nodal ratios in node-positive breast cancer. J Clin Oncol. 2006;24:2910-2916.
18. Vinh-Hung V, Verkooijen HM, Fioretta G, et al. Lymph node ratio as an alternative to pN staging in node-positive breast cancer. J Clin Oncol. 2009;27:1062-1068.
19. Truong PT, Woodward WA, Thames HD, et al. The ratio of positive to excised nodes identifies high-risk subsets and reduces inter-institutional differences in locoregional recurrence risk estimates in breast cancer patients with 1-3 positive nodes: An analysis of prospective data from british columbia and the M. D. anderson cancer center. Int J Radiat Oncol Biol Phys. 2007;68:59-65.
20. Mamounas E, Tang G, Bryant J, et al. Association between the 21-gene recurrence score assay (RS) and risk of loco-regional failure in node-negative, ER-positive breast cancer: Results from NSABP B-14 and NSABP B-20. Annual San Antonio Breast Cancer Symposium. 2005;abstract 29.
21. Voogd AC, Nielsen M, Peterse JL, et al. Differences in risk factors for local and distant recurrence after breast-conserving therapy or mastectomy for stage I and II breast cancer: Pooled results of two large european randomized trials. J Clin Oncol. 2001;19:1688-1697.
22. Overgaard M, Jensen MB, Overgaard J, et al. Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen: Danish breast cancer cooperative group DBCG 82c randomised trial. Lancet. 1999;353:1641-1648.
23. Zellars RC, Hilsenbeck SG, Clark GM, et al. Prognostic value of p53 for local failure in mastectomy-treated breast cancer patients. J Clin Oncol. 2000;18:1906-1913.
24. Pisansky TM, Ingle JN, Schaid DJ, et al. Patterns of tumor relapse following mastectomy and adjuvant systemic therapy in patients with axillary lymph node-positive breast cancer. impact of clinical, histopathologic, and flow cytometric factors. Cancer. 1993;72:1247-1260.
25. Mignano JE, Zahurak ML, Chakravarthy A, et al. Significance of axillary lymph node extranodal soft tissue extension and indications for postmastectomy irradiation. Cancer. 1999;86:1258-1262.
26. Buchholz TA, Hunt KK, Whitman GJ, et al. Neoadjuvant chemotherapy for breast carcinoma: Multidisciplinary considerations of benefits and risks. Cancer. 2003;98:1150-1160.
27. Bafaloukos D. Neo-adjuvant therapy in breast cancer. Ann Oncol. 2005;16(Suppl2):ii174-ii181.
28. Bear HD, Anderson S, Smith RE, et al. Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National surgical adjuvant breast and bowel project protocol B-27. J Clin Oncol. 2006;24:2019-2027.
29. Fisher B, Bryant J, Wolmark N, et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol. 1998;16:2672-2685.
30. Buchholz TA, Lehman CD, Harris JR, et al. Statement of the science concerning locoregional treatments after preoperative chemotherapy for breast cancer: A national cancer institute conference. J Clin Oncol. 2008;26:791-797.
31. Garg AK, Oh JL, Oswald MJ, et al. Effect of postmastectomy radiotherapy in patients <35 years old with stage II-III breast cancer treated with doxorubicin-based neoadjuvant chemotherapy and mastectomy. Int J Radiat Oncol Biol Phys. 2007;69:1478-1483.
32. McGuire SE, Gonzalez-Angulo AM, Huang EH, et al. Postmastectomy radiation improves the outcome of patients with locally advanced breast cancer who achieve a pathologic complete response to neoadjuvant chemotherapy. Int J Radiat Oncol Biol Phys. 2007;68:1004-1009.
33. Wolmark N, Wang J, Mamounas E, et al. Preoperative chemotherapy in patients with operable breast cancer: Nine-year results from national surgical adjuvant breast and bowel project B-18. J Natl Cancer Inst Monogr. 2001;30:96-102.
34. Huang EH, Tucker SL, Strom EA, et al. Postmastectomy radiation improves local-regional control and survival for selected patients with locally advanced breast cancer treated with neoadjuvant chemotherapy and mastectomy. J Clin Oncol. 2004;22:4691-4699.
35. Ahlborn TN, Gump FE, Bodian C, et al. Tumor to fascia margin as a factor in local recurrence after modified radical mastectomy. Surg Gynecol Obstet. 1988;166:523-526.
36. Truong PT, Olivotto IA, Speers CH, et al. A positive margin is not always an indication for radiotherapy after mastectomy in early breast cancer. Int J Radiat Oncol Biol Phys. 2004;58:797-804.
37. Jagsi R, Raad RA, Goldberg S, et al. Locoregional recurrence rates and prognostic factors for failure in node-negative patients treated with mastectomy: Implications for postmastectomy radiation. Int J Radiat Oncol Biol Phys. 2005;62:1035-1039.
38. Freedman GM, Fowble BL, Hanlon AL, et al. A close or positive margin after mastectomy is not an indication for chest wall irradiation except in women aged fifty or younger. Int J Radiat Oncol Biol Phys. 1998;41:599-605.
39. Katz A, Strom EA, Buchholz TA, et al. The influence of pathologic tumor characteristics on locoregional recurrence rates following mastectomy. Int J Radiat Oncol Biol Phys. 2001;50:735-742.
40. Floyd SR, Buchholz TA, Haffty BG, et al. Low local recurrence rate without postmastectomy radiation in node-negative breast cancer patients with tumors 5 cm and larger. Int J Radiat Oncol Biol Phys. 2006;66:358-364.
41. Katz A, Strom EA, Buchholz TA, et al. Locoregional recurrence patterns after mastectomy and doxorubicin-based chemotherapy: Implications for postoperative irradiation. J Clin Oncol. 2000;18:2817-2827.
42. McCammon R, Finlayson C, Schwer A, et al. Impact of postmastectomy radiotherapy in T3N0 invasive carcinoma of the breast: A surveillance, epidemiology, and end results database analysis. Cancer. 2008;113:683-68.
43. Mignano JE, Gage I, Piantadosi S, et al. Local recurrence after mastectomy in patients with T3pN0 breast carcinoma treated without postoperative radiation therapy. Am J Clin Oncol. 2007;30:466-472.
44. Taghian AG, Jeong JH, Mamounas EP, et al. Low locoregional recurrence rate among node-negative breast cancer patients with tumors 5 cm or larger treated by mastectomy, with or without adjuvant systemic therapy and without radiotherapy: Results from five national surgical adjuvant breast and bowel project randomized clinical trials. J Clin Oncol. 2006;24:3927-3932.
45. Helinto M, Blomqvist C, Heikkila P, et al. Post-mastectomy radiotherapy in pT3N0M0 breast cancer: Is it needed? Radiother Oncol. 1999;52:213-217.
46. Recht A, Edge SB, Solin LJ, et al. Postmastectomy radiotherapy: Clinical practice guidelines of the american society of clinical oncology. J Clin Oncol. 2001;19:1539-1569.
47. Truong PT, Olivotto IA, Whelan TJ, et al. Clinical practice guidelines for the care and treatment of breast cancer: 16. locoregional post-mastectomy radiotherapy. CMAJ. 2004;170:1263-1273.
48. Veronesi U, Valagussa P: Inefficacy of internal mammary nodes dissection in breast cancer surgery. Cancer. 1981;47:170-175.
49. Veronesi U, Cascinelli N, Greco M, et al. Prognosis of breast cancer patients after mastectomy and dissection of internal mammary nodes. Ann Surg. 1985;202:702-707.
50. Chen RC, Lin NU, Golshan M, et al. Internal mammary nodes in breast cancer: Diagnosis and implications for patient management - a systematic review. J Clin Oncol. 2008;26:4981-4989.
51. Fowble B, Hanlon A, Freedman G, et al. Internal mammary node irradiation neither decreases distant metastases nor improves survival in stage I and II breast cancer. Int J Radiat Oncol Biol Phys. 2000;47:883-894.
52. Estourgie SH, Tanis PJ, Nieweg OE, et al. Should the hunt for internal mammary chain sentinel nodes begin? an evaluation of 150 breast cancer patients. Ann Surg Oncol. 2003;10:935-941.
53. Kong A, Hunt K, Yi M, et al. The impact of primary nodal drainage on primary breast cancer. J Clin Oncol (ASCO Annual Meeting Abstracts). 2008;26:abstr 534.
54. Madsen E, Gobardhan P, Bongers V, et al. The impact on post-surgical treatment of sentinel lymph node biopsy of internal mammary lymph nodes in patients with breast cancer. Ann Surg Oncol. 2007;14:1486-1492.
55. Mansel RE, Goyal A, Newcombe RG, et al. Internal mammary node drainage and its role in sentinel lymph node biopsy: The initial ALMANAC experience. Clin Breast Cancer. 2004;5:279-284; discussion 285-286.
56. Yao MS, Kurland BF, Smith AH, et al. Internal mammary nodal chain drainage is a prognostic indicator in axillary node-positive breast cancer. Ann Surg Oncol. 2007;14:2985-2993.
57. Yu J, Li G, Li J, et al. The pattern of lymphatic metastasis of breast cancer and its influence on the delineation of radiation fields. Int J Radiat Oncol Biol Phys. 2005;61:874-878.
58. Veronesi U, Cascinelli N, Bufalino R, et al. Risk of internal mammary lymph node metastases and its relevance on prognosis of breast cancer patients. Ann Surg. 1983;198:681-684.
59. He Q, Jiang J, Yang X, et al. A pilot study on thoracoscopic internal mammary lymphatic chain dissection for breast cancer. Breast. 2008;17:568-573.
60. Veronesi U, Arnone P, Veronesi P, et al. The value of radiotherapy on metastatic internal mammary nodes in breast cancer. results on a large series. Ann Oncol. 2008;19:1553-1560.
61. Stemmer SM, Rizel S, Hardan I, et al. The role of irradiation of the internal mammary lymph nodes in high-risk stage II to IIIA breast cancer patients after high-dose chemotherapy: A prospective sequential nonrandomized study. J Clin Oncol. 2003;21:2713-2718.
62. Hojris I, Andersen J, Overgaard M, et al. Late treatment-related morbidity in breast cancer patients randomized to postmastectomy radiotherapy and systemic treatment versus systemic treatment alone. Acta Oncol. 2000;39:355-372.
63. Altundag M, Altundag K, Cengiz M, et al. The field of radiation therapy may effect health-related quality of life in patients with operable breast cancer. J Clin Oncol. 2004;22:1765; author reply 1765-1766.
64. Allen AM, Prosnitz RG, Ten Haken RK, et al. Body mass index predicts the incidence of radiation pneumonitis in breast cancer patients. Cancer J. 2005;11:390-398.
65. Porock D, Kristjanson L. Skin reactions during radiotherapy for breast cancer: The use and impact of topical agents and dressings. Eur J Cancer Care (Engl). 1999;8:143-153.
66. McQuestion M. Evidence-based skin care management in radiation therapy. Semin Oncol Nurs. 2006;22:163-173.
67. Pommier P, Gomez F, Sunyach MP, et al. Phase III randomized trial of calendula officinalis compared with trolamine for the prevention of acute dermatitis during irradiation for breast cancer. J Clin Oncol. 2004;22:1447-1453.
68. Meric F, Buchholz TA, Mirza NQ, et al. Long-term complications associated with breast-conservation surgery and radiotherapy. Ann Surg Oncol. 2002;9:543-549.
69. Lind PA, Wennberg B, Gagliardi G, et al. ROC curves and evaluation of radiation-induced pulmonary toxicity in breast cancer. Int J Radiat Oncol Biol Phys. 2006;64:765-770.
70. Lind PA, Marks LB, Hardenbergh PH, et al. Technical factors associated with radiation pneumonitis after local +/- regional radiation therapy for breast cancer. Int J Radiat Oncol Biol Phys. 2002;52:137-143.
71. Minor GI, Yashar CM, Spanos WJ,Jr, et al. The relationship of radiation pneumonitis to treated lung volume in breast conservation therapy. Breast J. 2006;12:48-52.
72. Taghian AG, Assaad SI, Niemierko A, et al. Is a reduction in radiation lung volume and dose necessary with paclitaxel chemotherapy for node-positive breast cancer? Int J Radiat Oncol Biol Phys. 2005;62:386-391.
73. Burstein HJ, Bellon JR, Galper S, et al. Prospective evaluation of concurrent paclitaxel and radiation therapy after adjuvant doxorubicin and cyclophosphamide chemotherapy for stage II or III breast cancer. Int J Radiat Oncol Biol Phys. 2006;64:496-504.
74. Ellerbroek N, Martino S, Mautner B, et al. Breast-conserving therapy with adjuvant paclitaxel and radiation therapy: Feasibility of concurrent treatment. Breast J. 2003;9:74-78.
75. Lind PA, Wennberg B, Gagliardi G, et al. ROC curves and evaluation of radiation-induced pulmonary toxicity in breast cancer. Int J Radiat Oncol Biol Phys. 2006;64:765-770.
76. Katayama N, Sato S, Katsui K, et al. Analysis of factors associated with radiation-induced bronchiolitis obliterans organizing pneumonia syndrome after breast-conserving therapy. Int J Radiat Oncol Biol Phys. 2009;73:1049-1054.
77. Ogo E, Komaki R, Fujimoto K, et al. A survey of radiation-induced bronchiolitis obliterans organizing pneumonia syndrome after breast-conserving therapy in japan. Int J Radiat Oncol Biol Phys. 2008;71:123-131.
78. Hojris I, Overgaard M, Christensen JJ, et al. Morbidity and mortality of ischaemic heart disease in high-risk breast-cancer patients after adjuvant postmastectomy systemic treatment with or without radiotherapy: Analysis of DBCG 82b and 82c randomised trials. radiotherapy committee of the danish breast cancer cooperative group. Lancet. 1999;354:1425-1430.
79. Berson AM, Emery R, Rodriguez L, et al. Clinical experience using respiratory gated radiation therapy: Comparison of free-breathing and breath-hold techniques. Int J Radiat Oncol Biol Phys. 2004;60:419-426.
80. Jagsi R, Moran JM, Kessler ML, et al. Respiratory motion of the heart and positional reproducibility under active breathing control. Int J Radiat Oncol Biol Phys. 2007;68:253-258.
81. Krauss DJ, Kestin LL, Raff G, et al. MRI-based volumetric assessment of cardiac anatomy and dose reduction via active breathing control during irradiation for left-sided breast cancer. Int J Radiat Oncol Biol Phys. 2005;61:1243-1250.
82. Coen JJ, Taghian AG, Kachnic LA, et al. Risk of lymphedema after regional nodal irradiation with breast conservation therapy. Int J Radiat Oncol Biol Phys. 2003;55:1209-1215.
83. Golshan M, Martin WJ, Dowlatshahi K. Sentinel lymph node biopsy lowers the rate of lymphedema when compared with standard axillary lymph node dissection. Am Surg. 2003;69:209-211; discussion 212.
84. Golshan M, Smith B: Prevention and management of arm lymphedema in the patient with breast cancer. J Support Oncol. 2006;4:381-386.
85. Hinrichs CS, Watroba NL, Rezaishiraz H, et al. Lymphedema secondary to postmastectomy radiation: Incidence and risk factors. Ann Surg Oncol. 2004;11:573-580.
86. Kocak Z, Overgaard J. Risk factors of arm lymphedema in breast cancer patients. Acta Oncol. 2000;39:389-392.
87. Silberman AW, McVay C, Cohen JS, et al. Comparative morbidity of axillary lymph node dissection and the sentinel lymph node technique: Implications for patients with breast cancer. Ann Surg. 2004;240:1-6.
88. Kligman L, Wong RK, Johnston M, et al. The treatment of lymphedema related to breast cancer: A systematic review and evidence summary. Support Care Cancer. 2004;12:421-431.
89. Obedian E, Fischer DB, Haffty BG. Second malignancies after treatment of early-stage breast cancer: Lumpectomy and radiation therapy versus mastectomy. J Clin Oncol. 2000;18:2406-2412.
90. Woodward WA, Strom EA, McNeese MD, et al. Cardiovascular death and second non-breast cancer malignancy after postmastectomy radiation and doxorubicin-based chemotherapy. Int J Radiat Oncol Biol Phys. 2003;57:327-335.
91. Galper S, Gelman R, Recht A, et al. Second nonbreast malignancies after conservative surgery and radiation therapy for early-stage breast cancer. Int J Radiat Oncol Biol Phys. 2002;52:406-414.
92. Harvey EB, Brinton LA. Second cancer following cancer of the breast in connecticut, 1935-82. Natl Cancer Inst Monogr. 1985;68:99-112.
93. Zablotska LB, Neugut AI. Lung carcinoma after radiation therapy in women treated with lumpectomy or mastectomy for primary breast carcinoma. Cancer. 2003;97:1404-1411.
94. Renella R, Verkooijen HM, Fioretta G, et al. Increased risk of acute myeloid leukaemia after treatment for breast cancer. Breast. 2006;15:614-619.
95. Gao X, Fisher SG, Emami B. Risk of second primary cancer in the contralateral breast in women treated for early-stage breast cancer: A population-based study. Int J Radiat Oncol Biol Phys. 2003;56:1038-1045.
96. Boice JD,Jr, Harvey EB, Blettner M, et al. Cancer in the contralateral breast after radiotherapy for breast cancer. N Engl J Med. 1992;326:781-785.
97. EORTC Breast Cancer Cooperative Group, EORTC Radiotherapy Group, Bijker N, et al. Breast-conserving treatment with or without radiotherapy in ductal carcinoma-in-situ: Ten-year results of european organisation for research and treatment of cancer randomized phase III trial 10853 - a study by the EORTC breast cancer cooperative group and EORTC radiotherapy group. J Clin Oncol. 2006;24:3381-3387.
98. Fisher B, Dignam J, Wolmark N, et al. Lumpectomy and radiation therapy for the treatment of intraductal breast cancer: Findings from national surgical adjuvant breast and bowel project B-17. J Clin Oncol. 1998;16:441-452.
99. Nielsen HM, Overgaard J, Grau C, et al. Audit of the radiotherapy in the DBCG 82 b&c trials - a validation study of the 1,538 patients randomised to postmastectomy radiotherapy. Radiother Oncol. 2005; 76:285-292.